CELG RT — Bristol-Myers Squibb Co Income Statement

0.000.00%

Last trade - 00:00

HealthcareHighly SpeculativeLarge CapSuper Stock

Annual income statement for Bristol-Myers Squibb Co, fiscal year end - December 31st, USD millions except per share, conversion factor applied.

	2021 December 31st	2022 December 31st	2023 December 31st	2024 December 31st	2025 December 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	10-K	10-K	10-K	10-K	8-K
Standards:	USG	USG	USG	USG	—
Status:	Final	Final	Final	Final	Final
Revenue
Total Revenue	46,385	46,159	45,006	48,300	48,194
Cost of Revenue
Gross Profit	36,784	36,085	34,404	36,351	35,000
Selling / General / Administrative Expenses
Research And Development
Depreciation and Amortization
Unusual Expense / Income
Other Operating Expenses
Total Operating Expenses	37,755	36,494	35,583	55,061	37,830
Operating Profit	8,630	9,665	9,423	-6,761	10,364
Total Net Non Operating Interest Income / Expense
Other Net Non Operating Costs
Net Income Before Taxes	8,098	7,713	8,440	-8,379	9,328
Provision for Income Taxes
Net Income After Taxes	7,014	6,345	8,040	-8,933	7,056
Minority Interest
Net Income Before Extraordinary Items
Net Income	6,994	6,327	8,025	-8,948	7,054
Adjustments to Net Income
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Diluted Net Income	6,994	6,327	8,025	-8,948	7,054
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	3.8	3.13	3.76	3.36	6.53
Dividends per Share